Mankind Pharma Ltd. Fundamental & Technical Research, Share Price Today

NSE : MANKIND
NIFTY : NIFTY Midcap 100
NIFTY SECTOR : Nifty Pharma

About Company

Mankind Pharma Limited is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices, and has an established track record of building and scaling brands in-house. It has created many brands in its pharmaceutical business.

Market Cap. ₹98,336 Cr.

52 Week - High/Low ₹3,055/1,901

P/E Ratio 47.35

P/B Ratio 10.22

Enterprise Value ₹97,776 Cr.

ROE % 20.98

RSI Value 51.36

EMA 50 2404.04

EMA 200 2418.63

Net Profit 1,823 Cr.

Net Profit 3year growth 68.15 Cr.

Net Profit 3 year (back) 1,084 Cr.

Debt to Equity 0.0 %

EPS Growth TTM 22.21 %

Current Ratio 3.44 %

100 Day SMA 2,536 Rs.

200 Day SMA 2,455 Rs.

21 Day SMA 2,322 Rs.

50 Day SMA 2,377 Rs.

Book Value 233 Rs.

EV/EBITDA Ratio 33

QoQ EPS Growth -33 %

QoQ Operating Profit Growth -1 %

QoQ Sales Growth -5 %

Sales Latest Quarter 2,397 Cr.

YoY Sales Growth 8 %

Market Cap. ₹98,336 Cr.

52 Week - High/Low ₹3,055/1,901

P/E Ratio 46.82

P/B Ratio 10.50

Enterprise Value ₹97,325 Cr.

ROE % 23.15

RSI Value 51.36

EMA 50 2404.04

EMA 200 2418.63

Net Profit 1,913 Cr.

Net Profit 3year growth 2.55 Cr.

Net Profit 3 year (back) 1,265 Cr.

Debt to Equity 0.02 %

EPS Growth TTM 18.07 %

Current Ratio 3.1 %

100 Day SMA 2,536 Rs.

200 Day SMA 2,455 Rs.

21 Day SMA 2,322 Rs.

50 Day SMA 2,377 Rs.

Book Value 227 Rs.

EV/EBITDA Ratio 29

QoQ EPS Growth -44 %

QoQ Operating Profit Growth -2 %

QoQ Sales Growth 5 %

Sales Latest Quarter 3,230 Cr.

YoY Sales Growth 24 %

Add Parameters

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages